drugset / Trial / NCT03187691
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Phase 2
Withdrawn
Matinas BioPharma Nanotechnologies, Inc.
The Clinical Trials Centre Cologne · collabUniversity of Cologne · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
A Non-randomized, prospective , multicenter, open uncontrolled study in patients with acute myelogenous (AML) or lymphoblastic leukaemia (ALL)
Timeline
- Start
- 2019-08
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 200 mg | Oral |
| Subject | Amphotericin B | Unknown | 400 mg | Oral |
| Subject | Amphotericin B | Unknown | 800 mg | Oral |